Mogamulizumab Q4week Dosing in Participants With R/R CTCL
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, Phase 2 study to evaluate the safety and tolerability of
mogamulizumab given Q4W following initial weekly induction in adult participants with
relapsed/refractory MF and SS subtypes of CTCL. The study is composed of a 28-day Screening
Period during which participants are screened for entry into this study, followed by a
treatment period of up to 2 years from Cycle 1 Day 1.
Phase:
Phase 2
Details
Lead Sponsor:
Kyowa Kirin Pharmaceutical Development, Inc. Kyowa Kirin, Inc.